Mitsubishi Tanabe Pharma meets a wide range of medical needs through the provision of distinctive ethical drugs, including drugs for autoimmune diseases, diabetes and kidney diseases, central nervous system diseases, and vaccines.

**Revenue (FY 2017)**

¥433.8 billion

---

**Domestic ethical drugs**

¥309.3 billion

**Priority Products in Fiscal 2017**

**Remicade**

**Indications** RA (including the prevention of structural joint damage), Behcet’s disease with refractory uveoretinitis, psoriasis vulgaris, psoriasis arthropathica, pustular psoriasis, erythrodermic psoriasis, ankylosing spondylitis, entero-Behcet’s disease, neuro-Behcet’s disease, vasculo-Behcet’s disease, Kawasaki disease, Crohn’s disease, ulcerative colitis

Revenue

¥64.6 billion

**Talion**

**Indications** Allergic rhinitis, urticaria, pruritus accompanying skin disease (eczema, dermatitis, prurigo, cutaneous pruritus)

Revenue

¥16.9 billion

**Lexapro**

**Indications** Depression, depressive symptoms, social anxiety disorder

Revenue

¥12.7 billion

**Simponi**

**Indications** RA (including the prevention of structural joint damage), ulcerative colitis

Revenue

¥32.1 billion

**Canaglu**

**Indication** Type 2 diabetes mellitus

Revenue

¥5.6 billion

**Tenelia**

**Indication** Type 2 diabetes mellitus

Revenue

¥17.5 billion

**Imusera**

**Indication** Multiple sclerosis (MS)

Revenue

¥4.7 billion

---

Note: Tanabe Seiyaku Hanbai was a sales subsidiary of the Company that sold generic drugs (see the “Explanation of Terms” section) and long-listed drugs (see the “Explanation of Terms” section) transferred from the Company. On October 1, 2017, the Company transferred all of its shares of Tanabe Seiyaku Hanbai to Nipro. Tanabe Seiyaku Hanbai’s fiscal 2017 revenue was ¥6.6 billion.
Influenza vaccine

**Indication** Prevention of influenza

Revenue ¥9.9 billion

Tetrabik

**Indications** Prevention of pertussis, diphtheria, tetanus, and polio

Revenue ¥8.7 billion

Varicella vaccine

**Indications** Prevention of chickenpox and herpes zoster in subjects aged 50 years or older

Revenue ¥5.2 billion

JEPIK V

**Indication** Prevention of Japanese encephalitis

Revenue ¥5.2 billion

Mearubik

**Indications** Prevention of attenuated measles and rubella

Revenue ¥5.0 billion

Vaccines

**Revenue by Business**

- Domestic ethical drugs 71.3%
- Overseas ethical drugs 8.9%
- OTC products 0.9%
- Others 0.7%
- Royalty revenue, etc. 18.2%

Overseas ethical drugs ¥38.5 billion

Radicava

**Indication** Amyotrophic lateral sclerosis (ALS)

Revenue ¥12.3 billion

Gilenya

**Indication** Multiple sclerosis (MS)

Royalty Revenue ¥57.7 billion

Invokana

**Indication** Type 2 diabetes mellitus

Royalty Revenue ¥13.9 billion

OTC products ¥3.7 billion

- Flucort f
- Tanabe Ichoyaku Urso
- Aspara Drink α

Others ¥3.0 billion

Contract manufacturing of other companies' products, etc.